Avid Bioservices, Inc. has signed a manufacturing supply agreement with Catalyst Biosciences to produce clinical-grade material for Catalyst’s drug candidate, CB 813, a new version of factor VIIa for the treatment of acute bleeding in hemophilia patients.     Under the terms of the agreement, Avid will begin manufacturing drug supply under cGMP regulations and provide cell bank preparation, process development, and preparation of the manufacturing portion of the NDA.  Further details we...